About STAAR Surgical (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Industry, Sector and Symbol
Industry MED PRODS
Sub-IndustryHealth Care Supplies
Trailing P/E Ratio-405
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$90.61 million
Price / Sales7.38
Cash Flow$0.09 per share
Price / Cash178.31
Book Value$1.04 per share
Price / Book15.53
Return on Equity-2.28%
Return on Assets-1.34%
STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions
What is STAAR Surgical's stock symbol?
STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical's earnings last quarter?
STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday, February, 28th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.01. The medical instruments supplier had revenue of $24.85 million for the quarter. STAAR Surgical had a negative net margin of 2.36% and a negative return on equity of 2.28%. View STAAR Surgical's Earnings History.
When will STAAR Surgical make its next earnings announcement?
Where is STAAR Surgical's stock going? Where will STAAR Surgical's stock price be in 2018?
2 Wall Street analysts have issued 12-month price objectives for STAAR Surgical's shares. Their forecasts range from $20.00 to $21.00. On average, they anticipate STAAR Surgical's share price to reach $20.50 in the next year. View Analyst Ratings for STAAR Surgical.
Who are some of STAAR Surgical's key competitors?
Some companies that are related to STAAR Surgical include TG Therapeutics (TGTX), Glaukos (GKOS), Intersect ENT (XENT), Atrion (ATRI), Natus Medical (BABY), OraSure Technologies (OSUR), Orthofix International (OFIX), MacroGenics (MGNX), Owens & Minor (OMI), Luminex (LMNX), K2M Group (KTWO), Cardiovascular Systems (CSII), Eagle Pharmaceuticals (EGRX), Cerus (CERS), AtriCure (ATRC), Cryolife (CRY), LeMaitre Vascular (LMAT) and Invacare (IVC).
Who are STAAR Surgical's key executives?
STAAR Surgical's management team includes the folowing people:
- Caren L. Mason, President, Chief Executive Officer, Director
- Deborah J. Andrews, Chief Financial Officer, Vice President
- Hans-Martin Blickensdoerfer, Senior Vice President - Commercial Operations for Europe, Middle East, Africa, Latin America and China.
- James E. Francese, Senior Vice President of North American and APAC
- Keith Holliday Ph.D., Chief Technology Officer, Vice President
- Surindra Mann, Vice President - Global Financial Planning and Analysis
- , Bio & Compensation -
- William Walter Goodmen, Vice President - Global Human Resources
- Jon K. Hayashida, Vice President - Global Clinical and Medical Affairs
- , Bio & Compensation -
- Philippe Subrin, Vice President-ICL Manufacturing
- Samuel J. Gesten, Vice President - Business Development, Chief Legal Officer and Secretary
Has STAAR Surgical been receiving favorable news coverage?
News stories about STAA stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. STAAR Surgical earned a news impact score of 0.08 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 46.25 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are STAAR Surgical's major shareholders?
STAAR Surgical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LLC (8.50%), BlackRock Inc. (6.34%), Millennium Management LLC (1.12%), Cortina Asset Management LLC (1.10%), Grandeur Peak Global Advisors LLC (0.80%) and Renaissance Technologies LLC (0.77%). Company insiders that own STAAR Surgical stock include Broadwood Partners Lp, Hans-Martin Blickensdoerfer, Keith Holliday and Richard A Meier. View Institutional Ownership Trends for STAAR Surgical.
Which major investors are selling STAAR Surgical stock?
STAA stock was sold by a variety of institutional investors in the last quarter, including Grandeur Peak Global Advisors LLC, Cortina Asset Management LLC, Millrace Asset Group Inc., Metropolitan Life Insurance Co. NY, Creative Planning, Palo Alto Investors LLC, Rice Hall James & Associates LLC and Rhumbline Advisers. View Insider Buying and Selling for STAAR Surgical.
Which major investors are buying STAAR Surgical stock?
STAA stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Folger Hill Asset Management LP, Deutsche Bank AG, Two Sigma Investments LP, BlackRock Inc., Barrow Hanley Mewhinney & Strauss LLC, Two Sigma Advisers LP and Algert Global LLC. View Insider Buying and Selling for STAAR Surgical.
How do I buy shares of STAAR Surgical?
Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STAAR Surgical's stock price today?
One share of STAA stock can currently be purchased for approximately $16.25.
How big of a company is STAAR Surgical?
STAAR Surgical has a market capitalization of $675.11 million and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.
How can I contact STAAR Surgical?
STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]
MarketBeat Community Rating for STAAR Surgical (STAA)MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
STAAR Surgical (NASDAQ:STAA) Earnings History and Estimates Chart
STAAR Surgical (NASDAQ STAA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/28/2018||Q4 2017||$0.03||$0.02||$24.85 million||View||Listen|
|11/8/2017||Q3 2017||$0.02||$0.02||$23.47 million||View||N/A|
|8/2/2017||Q2 2017||($0.05)||($0.01)||$22.15 million||$21.90 million||View||Listen|
|5/3/2017||Q1 2017||($0.05)||($0.05)||$20.35 million||View||Listen|
|3/2/2017||Q4 2016||($0.02)||$0.02||$22.25 million||$22.10 million||View||Listen|
|11/3/2016||Q316||($0.04)||($0.02)||$20.70 million||$20.05 million||View||Listen|
|8/3/2016||Q216||($0.05)||($0.05)||$19.88 million||$21.00 million||View||Listen|
|5/11/2016||Q116||($0.17)||($0.01)||$19.60 million||$19.30 million||View||Listen|
|3/2/2016||Q415||($0.02)||$0.01||$19.11 million||$20.90 million||View||Listen|
|10/28/2015||Q315||($0.04)||($0.04)||$17.87 million||$18.80 million||View||Listen|
|7/29/2015||Q2 2015||($0.02)||$18.20 million||$18.66 million||View||N/A|
|4/29/2015||Q115||($0.04)||$0.03||$17.85 million||$18.90 million||View||Listen|
|2/25/2015||Q414||($0.05)||($0.03)||$16.60 million||$16.60 million||View||Listen|
|10/30/2014||Q314||$0.02||($0.04)||$19.53 million||$18.20 million||View||Listen|
|7/30/2014||Q214||$0.03||$0.01||$19.80 million||$20.05 million||View||Listen|
|4/28/2014||Q114||$0.01||$0.04||$19.44 million||$20.20 million||View||Listen|
|2/26/2014||Q413||$0.02||$0.02||$18.98 million||$18.90 million||View||Listen|
|10/30/2013||Q313||$0.02||$0.04||$17.35 million||$17.10 million||View||Listen|
|7/31/2013||Q2 2013||$0.04||$0.05||$17.40 million||$18.20 million||View||Listen|
|5/1/2013||Q1 2013||$0.04||$0.08||$17.27 million||$18.00 million||View||Listen|
|2/27/2013||Q4 2012||$0.03||$0.01||$17.55 million||$16.50 million||View||Listen|
|10/31/2012||Q312||$0.01||$0.04||$16.78 million||$15.90 million||View||N/A|
STAAR Surgical (NASDAQ:STAA) Earnings Estimates
Current Year EPS Consensus Estimate: $0.1 EPS
Dividend History for STAAR Surgical (NASDAQ:STAA)
No dividend announcements for this company have been tracked by MarketBeat.com
STAAR Surgical (NASDAQ STAA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 78.95%
STAAR Surgical (NASDAQ STAA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/21/2017||Keith Holliday||VP||Sell||6,000||$16.65||$99,900.00||45,969|| |
|12/9/2016||Hans-Martin Blickensdoerfer||VP||Sell||25,000||$11.14||$278,500.00||137,380|| |
|6/29/2016||Broadwood Partners Lp||Major Shareholder||Buy||14,144||$5.24||$74,114.56|| |
|5/25/2016||Broadwood Partners Lp||Major Shareholder||Buy||77,842||$5.16||$401,664.72|| |
|5/24/2016||Broadwood Partners Lp||Major Shareholder||Buy||70,000||$5.16||$361,200.00|| |
|5/23/2016||Broadwood Partners Lp||Major Shareholder||Buy||3,138||$5.24||$16,443.12|| |
|5/20/2016||Richard A Meier||Director||Sell||25,000||$5.35||$133,750.00||27,149|| |
|5/17/2016||Broadwood Partners Lp||Major Shareholder||Buy||9,313||$5.23||$48,706.99|| |
|5/16/2016||Broadwood Partners Lp||Major Shareholder||Buy||336,210||$5.49||$1,845,792.90|| |
|2/9/2016||Broadwood Partners Lp||Major Shareholder||Buy||91,770||$6.25||$573,562.50|| |
|2/3/2016||Broadwood Partners Lp||Major Shareholder||Buy||121,599||$6.40||$778,233.60|| |
|2/1/2016||Broadwood Partners Lp||Major Shareholder||Buy||65,983||$6.48||$427,569.84|| |
|1/27/2016||Broadwood Partners Lp||Major Shareholder||Buy||239,013||$6.63||$1,584,656.19|| |
|1/26/2016||Broadwood Partners Lp||Major Shareholder||Buy||112,900||$6.60||$745,140.00|| |
|1/25/2016||Broadwood Partners Lp||Major Shareholder||Buy||81,752||$6.74||$551,008.48|| |
|1/20/2016||Broadwood Partners Lp||Major Shareholder||Buy||72,858||$6.75||$491,791.50|| |
|1/15/2016||Broadwood Partners Lp||Major Shareholder||Buy||135,725||$6.73||$913,429.25|| |
|1/11/2016||Broadwood Partners Lp||Major Shareholder||Buy||86,586||$6.83||$591,382.38|| |
|1/7/2016||Broadwood Partners Lp||Major Shareholder||Buy||267,047||$6.95||$1,855,976.65|| |
|1/4/2016||Broadwood Partners Lp||Major Shareholder||Buy||165,461||$7.11||$1,176,427.71|| |
|9/29/2015||Broadwood Partners Lp||Major Shareholder||Buy||311,099||$7.08||$2,202,580.92|| |
|8/25/2015||Broadwood Partners Lp||Major Shareholder||Buy||188,881||$7.17||$1,354,276.77|| |
|8/24/2015||Caren L Mason||CEO||Buy||10,000||$7.34||$73,400.00||14,500|| |
|4/6/2015||Samuel J Gesten||VP||Sell||3,223||$7.14||$23,012.22|| |
|3/3/2015||Robin Hughes||VP||Sell||23,253||$15.82||$367,862.46|| |
|11/19/2014||Broadwood Partners Lp||Major Shareholder||Buy||189,646||$8.64||$1,638,541.44|| |
|11/18/2014||Broadwood Partners Lp||Major Shareholder||Buy||39,400||$8.67||$341,598.00|| |
|11/17/2014||Broadwood Partners Lp||Major Shareholder||Buy||118,200||$8.63||$1,020,066.00|| |
|11/10/2014||Broadwood Partners Lp||Major Shareholder||Buy||500||$8.79||$4,395.00|| |
|11/7/2014||Broadwood Partners Lp||Major Shareholder||Buy||80,000||$8.92||$713,600.00|| |
|11/4/2014||Broadwood Partners Lp||Major Shareholder||Buy||260,341||$9.20||$2,395,137.20|| |
|5/15/2014||John Moore||Director||Sell||2,800||$14.87||$41,636.00||76,000|| |
|3/19/2014||James Francese||VP||Sell||16,666||$17.22||$286,988.52||21,960|| |
|3/17/2014||Robin Hughes||VP||Sell||5,672||$16.61||$94,211.92||56,818|| |
|9/4/2013||Deborah Andrews||CFO||Sell||50,000||$12.88||$644,000.00||36,400|| |
|8/20/2013||Deborah Andrews||CFO||Sell||33,515||$11.65||$390,449.75||36,400|| |
|8/12/2013||Deborah Andrews||CFO||Sell||9,079||$11.62||$105,497.98||22,621|| |
|8/7/2013||Deborah Andrews||CFO||Sell||11,721||$11.79||$138,190.59||24,639|| |
|5/9/2013||Deborah J Andrews||CFO||Sell||5,000||$8.96||$44,800.00|| |
|12/11/2012||John C Moore||Director||Buy||5,000||$5.46||$27,300.00|| |
|11/15/2012||Broadwood Partners Lp||Major Shareholder||Buy||2,618||$5.00||$13,090.00|| |
|11/15/2012||Mark B Logan||Director||Buy||3,600||$5.22||$18,792.00|| |
|11/14/2012||Barry G Caldwell||CEO||Buy||5,000||$5.04||$25,200.00|| |
|11/2/2012||Broadwood Partners Lp||Major Shareholder||Buy||22,572||$5.00||$112,860.00|| |
|8/9/2012||Barry G Caldwell||CEO||Buy||5,000||$6.57||$32,850.00|| |
STAAR Surgical (NASDAQ STAA) News Headlines
STAAR Surgical (NASDAQ:STAA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
STAAR Surgical (NASDAQ:STAA) Income Statement, Balance Sheet and Cash Flow Statement
STAAR Surgical (NASDAQ STAA) Stock Chart for Tuesday, March, 20, 2018